HF-158K1 by HighField Biopharmaceuticals for Bladder Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Bladder Cancer.

FDA again rejects AbbVie’s continuous infusion therapy for Parkinson’s

The FDA has rejected a new Parkinson’s drug from AbbVie for a second time. Regulators turned away ABBV-951, a 24-hour infusion therapy to treat advanced

June 26, 2024

Pharmalittle: Biden’s NIH nominee will get a hearing; top Democrat backs bill to ban PBM spread pricing

Good morning, Jason Mast here filling in for Ed. Today, I’m drinking a cup of tepid corporate chain coffee, black with a touch of hazelnut,

September 11, 2023

BIO-Europe® Celebrates 30th Anniversary with Landmark Event in Stockholm – Biotech Investments

EQS-News: EBD Group / Key word(s): Conference BIO-Europe® Celebrates 30th Anniversary with Landmark Event in Stockholm 05.08.2024 / 14:00 CET/CEST The issuer is solely responsible

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.